Preclinical Studies of Signaling Pathways in a Mutant Mouse Model of Hormone-Refractory Prostate Cancer

Abstract

We have been investigating targeted therapies for the treatment of advanced prostate cancer using a genetically-engineered mouse model of the disease. We performed pre-clinical studies to examine the consequences of combinatorial inhibition of these signaling pathways using Rapamycin, an inhibitor of mTOR, and PD0325901, a MEK inhibitor, is potently anti-tumorigenic in mouse models of castration-resistant prostate cancer. Current studies reported herein demonstrate that this combination is also effective for tumor suppression of advanced prostate cancer models and can improve survival. Studies in progress are evaluating new combinations and also evaluating molecular changes in response to therapy.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Feb 01, 2010
Accession Number
ADA521766

Entities

People

  • Cory Abate-shen

Organizations

  • Columbia University

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Cancer
  • Castration
  • Cell Line
  • Cells
  • Combination Therapy
  • Culture Techniques
  • Diseases And Disorders
  • Gene Expression
  • Inhibition
  • Inhibitors
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Survival

Fields of Study

  • Biology

Readers

  • Oncology (Cancer Research).
  • Prostate Cancer Biology.

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech